Al Sandrock notches another post-Biogen role — and it's taking him right back onto familiar ground
Al Sandrock has landed another post-Biogen gig for this next chapter in his biotech career following the catastrophic collapse of his campaign for Aduhelm.
The R&D expert has lined up a board post for Verge Genomics, an AI-powered startup that has its sights set on a drug program for ALS, followed by new work on Parkinson’s — putting the CNS-focused Sandrock right back into a research arena, where he has fought many, many times before.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.